Xeris Forecasts $390M 2026 Revenue as Recorlev Gains, XP-8121 Nears Phase III
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
xerisbiopharmaceuticals
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Xeris Biopharma Holdings announced a 2026 revenue forecast of $385 million to $390 million on August 6, 2026, as its cortisol synthesis inhibitor Recorlev expands and a Phase III trial for its congenital adrenal hyperplasia candidate, XP-8121, targets a start by year-end. The projection comes as Xeris's stock, trading under the ticker TGT, shows modest pressure, priced at $147.41 as of 19:16 UTC today, representing a daily decline of 0.48% within a session range of $146.31 to $149.44. The announcement signals the company's transition from a development-stage entity to a commercial-stage organization with a growing portfolio of endocrine disorder treatments.
The revenue forecast arrives during a pivotal period for mid-cap biopharma firms navigating a capital environment where the 10-year Treasury yield remains elevated above 4.2%. The last time a major endocrine-focused biotech projected revenue exceeding $380 million ahead of a key Phase III start was Neurocrine Biosciences in February 2024, prior to its successful valbenazine launch for tardive dyskinesia. Xeris's specific catalyst chain hinges on two near-term execution points: continued market penetration for Recorlev, which treats endogenous Cushing's syndrome, and the formal initiation of the XP-8121 Phase III program. The timing is critical as investors increasingly penalize developmental delays while rewarding concrete commercial traction and clear pipeline milestones in the healthcare sector.
The announced 2026 revenue target of $385 million to $390 million represents a significant forward-looking figure for Xeris. As of the market close, the stock traded at $147.41, down 0.48% on the day, underperforming the broader S&P 500 healthcare sector's year-to-date gain of approximately 6.5%. The day's trading range was contained between $146.31 and $149.44. For context, a revenue projection in this range implies a forward price-to-sales ratio of approximately 3.8x based on the current market capitalization implied by the $147.41 share price, which is in line with the peer median for commercial-stage rare disease companies. The 0.48% decline contrasts with the stock's 52-week performance, which has seen periods of volatility exceeding 5% on single-day moves related to clinical and regulatory news.
| Metric | Value | Comparison Point |
|---|---|---|
| 2026 Revenue Forecast | $385M - $390M | Forward P/S ~3.8x |
| TGT Share Price | $147.41 | -0.48% daily change |
| Daily Trading Range | $146.31 - $149.44 | ~2.1% intraday spread |
| Sector Benchmark | SPX Healthcare YTD +6.5% | TGT underperformance on day |
The forecast provides a tangible valuation anchor for Xeris, potentially stabilizing the stock after a period of speculation on its pipeline's value. Second-order effects are clearest within the endocrine and rare disease subsector. Peers like Crinetics Pharmaceuticals and Spruce Biosciences could see increased investor scrutiny on their commercial readiness and revenue projection timelines. A key risk to the bullish thesis is execution risk; the $385-390 million target assumes successful Recorlev adoption and no delays in the XP-8121 trial initiation, which carries inherent clinical and regulatory uncertainty. Positioning data suggests institutional investors have been net buyers of healthcare stocks with visible mid-term revenue pathways, while short interest in high-burn-rate biotechs without near-term catalysts remains elevated. Flow is likely to concentrate on companies demonstrating a clear bridge from clinical development to commercial sales.
Market focus will immediately shift to two specific, dated catalysts. First, investors will monitor the official commencement of the XP-8121 Phase III trial, expected by December 31, 2026, for any announcement regarding first patient dosing. Second, quarterly earnings reports, beginning with the Q3 2026 release likely in early November, will provide the first check on Recorlev's sales trajectory against the implied run-rate for the $385-390 million annual target. Key technical levels to watch for TGT include the day's low of $146.31 as near-term support and the $150 psychological resistance level. A breach above $150 on high volume could signal renewed confidence, while a sustained break below $145 may indicate skepticism about the forecast's achievability.
For retail investors, the $385-390 million forecast provides a concrete benchmark against which to measure the company's quarterly performance. It shifts the investment narrative from pure pipeline speculation to execution on commercial sales, a transition that typically reduces volatility but increases accountability to quarterly results. Investors should compare subsequent earnings reports against the implied quarterly revenue needed to hit the annual target, approximately $96 million per quarter.
Recorlev's expansion directly contributes to the revenue forecast, reducing reliance on capital markets for funding and improving the company's cash flow profile. As a commercial product, its sales generate gross margin, which can be reinvested into the XP-8121 Phase III program and other R&D, potentially lowering future dilution risk from equity offerings. Successful expansion validates the company's commercial capabilities for future product launches.
Historical success rates for Phase III trials in endocrine disorders like congenital adrenal hyperplasia are higher than the industry average for oncology but carry specific risks. Analysts at firms like EvaluatePharma have cited Phase III success rates for metabolic/endocrine drugs around 65-70%, compared to an overall industry average near 55%. The specific mechanism and prior Phase II data for XP-8121 will be critical factors in its probability of success.
Xeris's revenue forecast sets a high commercial bar that the stock must now grow into, shifting investor focus squarely to execution.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.